Distribution of I-125-labeled crotamine in mice tissues

Crotamine is a strong basic polypeptide from Crotalus durissus terrificus (Cdt) venom composed of 42 amino acid residues tightly bound by three disulfide bonds. It causes skeletal muscle spasms leading to spastic paralysis of hind limbs in mice. The objective of this paper was to study the distribution of crotamine injected intraperitoneally (ip) in mice. Crotamine was purified from Cdt venom by gel filtration, followed by ion exchange chromatography, using a fast-performance liquid chromatography (FPLC) system. Purified crotamine was irradiated at 2 kGy in order to detoxify. Both native and irradiated proteins were labeled with 125, using chloramine T method, and separated by get filtration. Male Swiss mice were injected ip with 0.1 mL (2 x 10(6) cpm/mouse) of I-125 native or irradiated crotamine. At various time intervals, the animals were killed by ether inhalation and blood, spleen, liver, kidneys, brain, lungs, heart, and skeletal muscle were collected in order to determine the radioactivity content. The highest levels of radioactivity were found in the kidneys and the liver, and the lowest in the brain. (c) 2006 Elsevier Ltd. All rights reserved.

125 GeV scalar boson and SU(NTC)⊗ - SU(3) L⊗ - U(1)X models

We verify that SU(N)TC⊗ - SU(3) L⊗ - U(1)X models, where the gauge symmetry breaking is totally dynamical and promoted by the non-Abelian technicolor group and the strong Abelian interactions, are quite constrained by the LHC data. The theory contains a T quark self-energy involving the mixing between the neutral gauge bosons, which introduces the coupling between the light and heavy composite scalar bosons of the model. We determine the lightest scalar boson mass for these models from an effective action for composite operators, assuming details about the dynamics of the strong interaction theories. Comparing the value of this mass with the ATLAS and CMS observation of a new boson with a mass M∼125 GeV and considering the lower bound determined by the LHC Collaboration on the heavy neutral gauge boson (Z′) present in these models, we can establish constraints on the possible models. For example, if SU(N)TC≡SU(2)TC, with technifermions in the fundamental representation, the model barely survives the confrontation with the LHC data. © 2013 American Physical Society.

Observation of a new boson with mass near 125 GeV in pp collisions at √=7 and 8 TeV

A detailed description is reported of the analysis used by the CMS Collaboration in the search for the standard model Higgs boson in pp collisions at the LHC, which led to the observation of a new boson. The data sample corresponds to integrated luminosities up to 5.1 fb-1 at √=7 TeV, and up to 5.3 fb-1 at √ s=8 TeV. The results for five Higgs boson decay modes γγ, ZZ, WW, ττ, and bb, which show a combined local significance of 5 standard deviations near 125 GeV, are reviewed. A fit to the invariant mass of the two high resolution channels, γγ and ZZ → 4ℓ, gives a mass estimate of 125.3 ± 0.4 (stat.) ± 0.5 (syst.) GeV. The measurements are interpreted in the context of the standard model Lagrangian for the scalar Higgs field interacting with fermions and vector bosons. The measured values of the corresponding couplings are compared to the standard model predictions. The hypothesis of custodial symmetry is tested through the measurement of the ratio of the couplings to the W and Z bosons. All the results are consistent, within their uncertainties, with the expectations for a standard model Higgs boson. [Figure not available: see fulltext.] © 2013 CERN for the benefit of the CMS collaboration.

The 125 GeV boson: A composite scalar?

Assuming that the 125 GeV particle observed at the LHC is a composite scalar and responsible for the electroweak gauge symmetry breaking, we consider the possibility that the bound state is generated by a non-Abelian gauge theory with dynamically generated gauge boson masses and a specific chiral symmetry breaking dynamics motivated by confinement. The scalar mass is computed with the use of the Bethe-Salpeter equation and its normalization condition as a function of the SU(N) group and the respective fermionic representation. If the fermions that form the composite state are in the fundamental representation of the SU(N) group, we can generate such a light boson only for one specific number of fermions for each group. We address the uncertainties underlying this result, when considering the strong dynamics in isolation. © 2013 American Physical Society.

Evidence for the 125 GeV Higgs boson decaying to a pair of tau leptons

A search for a standard model Higgs boson decaying into a pair of tau leptons is performed using events recorded by the CMS experiment at the LHC in 2011 and 2012. The dataset corresponds to an integrated luminosity of 4.9 fb(-1) at a centre-of-mass energy of 7 TeV and 19.7 fb(-1) at 8 TeV. Each tau lepton decays hadronically or leptonically to an electron or a muon, leading to six different final states for the tau-lepton pair, all considered in this analysis. An excess of events is observed over the expected background contributions, with a local significance larger than 3 standard deviations for m (H) values between 115 and 130 GeV. The best fit of the observed H -> tau tau signal cross section times branching fraction for m(H) = 125 GeV is 0.78 +/- 0.27 times the standard model expectation. These observations constitute evidence for the 125 GeV Higgs boson decaying to a pair of tau leptons.

Braquiterapia com sementes de iodo-125: manufatura e tratamento

According to the National Institute of Cancer – INCA, 466.730 new cancer cases will occur in Brazil in 2009. Prostate and Lung cancer in man are the most incident types (in exception of the non-melanoma cancer). The brachytherapy with 125-iodine sources is an important method of prostate cancer treatment. The implant with iodine-125 seeds uses aproximately 100 seeds that are imported impossibilitating the treatment in large scale. For this reason, a multidisciplinary group was created at the Energetic and Nuclear Research Institute – Radiation Technology Center (IPEN –CTR / SP) to develop a national 125-iodine source and established a facility for local production. The seeds manufacture in Brazil will diminish the cost of treatment and prostate brachytherapy will be offered to more patients. This work aim is to observe and discuss the methods used in seeds manufacture there are being developed in Brazil and to present an prostate cancer case folloied in A.C. Camargo Hospital. The 125-iodine is adsorbed in an silver wire, then deposited at titanium coat. The weld is made by an process of plasm sealing. The seeds goes through several test to guarantee that there is no leakage. The result is an high quality and cheaper product. The implant tecnique is an fast and save procedure. The medical physicst preplan the case to stipulate the quantity of seeds there will be used. At the dat of the implant the medical physicst replan the procedure due to changes of volume in the organ. That assure the correct dose distribution in the target. Besides, the 125-iodine low energy is absorbed at the volume of interrest saving sourronding healthy tissues such as the rectum and the urethra

Dirac gaugions, R symmetry and the 125 GeV Higgs

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Colorless top partners, a 125 GeV Higgs boson, and the limits on naturalness

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Síntese e caracterização da MOF NH2-MIL-125(Ti) e sua aplicação como catalisador na reação de condensação de Knoevenagel

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Fennell Infirmary Records - Accession 227 - M97 (125)

The Fennell Infirmary Records consist of photocopies of newspaper articles, photographs, and biographical data concerning Dr. William Wallace Fennell (1869-1926), a physician and founder of Fennell Infirmary in Rock Hill, SC. The Fennell Infirmary was started in 1910.

Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution

Brachytherapy is an adequate option as monotherapy for localised prostate cancer. The objective of this study was to evaluate and compare biochemical failure free survival (BFFS) after low-dose-rate brachytherapy (LDRB) alone for patients with prostate cancer using ASTRO and Phoenix criteria, and detect prognostic factors. Data on 220 patients treated between 1998 and 2002 with LDRB were retrospectively analysed. Neoadjuvant hormone therapy was used in 74 (33.6%) patients. Median follow-up was 53.5 months (24-116). Five year BFFS was 83.0% and 83.7% using, respectively, the ASTRO and Phoenix criteria. Low -and intermediate-risk patients presented, respectively, 86.7% and 77.8% 5-year BFFS using the ASTRO definition (p=0.069), and 88.5% and 78.6% considering the Phoenix criteria (p=0.016). Bounce was observed in 66 (30%) patients. Multivariate analysis detected PSA at diagnosis < 10 ng/ml and less than 50% positive biopsy fragments as favourable prognostic factors, regarding BF using both criteria. For the Phoenix criteria, also Gleason score < 7 and low-risk group were identified as independent favourable prognostic factors. LDRB alone should be considered mostly for low-risk patients. PSA level was a strong independent prognostic factor. We support the use of the Phoenix criteria for detection of BF in patients submitted to LDRB alone.

Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study

Objective: To evaluate serum concentrations of CA-125 and soluble CD-23 and to correlate them with clinical symptoms, localization and stage of pelvic endometriosis and histological classification of the disease. Methods: Blood samples were collected from 44 women with endometriosis and 58 without endometriosis, during the first three days (1st sample) and during the 7th, 8th and 9th day (2nd sample) of the menstrual cycle. Measurements of CA-125 and soluble CD-23 were performed by ELISA. Mann-Whitney U test was used for age, pain evaluations (visual analog scale) and biomarkers concentrations. Results: Serum levels Of CA-125 were higher in endometriosis patients when compared to the control group during both periods of the menstrual cycle evaluated in the study. This marker was also elevated in women with chronic pelvic pain, deep dyspareunia (2nd sample), dysmenorrhea (both samples) and painful defecation during the menstrual flow (2nd sample). CA-125 concentration was higher in advanced stages of the disease in both samples and also in women with ovarian endometrioma. Concerning CD-23, no statistically significant differences were observed between groups. Conclusion: The concentrations of CA-125 were higher in patients with endometriosis than in patients without the disease. No significantly differences were observed for soluble CD-23 levels between groups.